CSPC Innovation Pharmaceutical (300765.SZ): SYS6041 (Folic Acid Receptor ADC) Receives Approval for Drug Clinical Trials.

CSPC Innovation Pharmaceutical (300765.SZ) announced that its controlling subsidiary, CSPC PHARMA Geminium Biopharmaceutical Co., Ltd. (hereinafter referred to as "Geminium Biopharm"), recently received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for SYS6041 (Folate Receptor ADC), and will soon begin clinical trials. SYS6041 is an antibody-drug conjugate targeting the folate receptor alpha (FR). The FR antibody part binds to the FR on the surface of tumor cells, enters the tumor cells through endocytosis, and releases small molecule toxins - topoisomerase I inhibitors - after tissue protease-specific cleavage, thereby killing the tumor cells and exhibiting bystander effects to nonspecifically kill surrounding tumor tissue cells. SYS6041's potential indications include gynecologic tumors and lung cancer. Existing data from Phase I clinical trials show that SYS6041 is competitive among similar products. The approved combined drug clinical trial for SYS6041 will further expand the clinical application scenarios of SYS6041.